Seeking Alpha

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...
Yahoo

Keytruda and Padcev could become cancer’s power couple

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Oncology drug development is no longer a singles market as ...
FiercePharma

Merck's partner Kelun touts phase 3 win for ADC-Keytruda combo in first-line lung cancer

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
Seeking Alpha

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain ...

Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...
Healthline

Keytruda Qlex Overview: Side Effects, Uses, Dosage, and More

Keytruda Qlex (pembrolizumab and berahydaluronidas alfa-pmph) is a prescription drug approved to treat different types of cancer, such as non-small cell lung cancer and head and neck cancer. Keytruda ...
Morningstar

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 ...

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 ...